Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

A - Agilent Technologies, Inc. Latest News | Finranks

Home

A

A

Agilent Technologies, Inc. (A)

NYQ – Real Time Price. Currency in USD

110.24

-3.24 (-2.86%)

At close: Mar 27, 2026, 4:00 PM EDT

110.20

-0.04 (-0.04%)

After-hours: Mar 27, 2026, 7:56 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Why Is Agilent (A) Down 6.2% Since Last Earnings Report?

Why Is Agilent (A) Down 6.2% Since Last Earnings Report?

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda.

Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript

Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript

Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript

Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More

Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More

Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies ( NYSE:A ) while trimming its price target on Icon PLC ( NASDAQ:ICLR ) following a turbulent earnings season for the sector.

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so.

Videos

No Data

There is no data to display

Press releases

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica.

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda.

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so.

Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies

Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies

Denver, CO and London, UK, 9 March 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, and Biocare Medical (“Biocare”), a global leader of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, today announce that Biocare has entered into an agreement to be acquired by Agilent Technologies (“Agilent”, NYSE:A), a prominent player in life sciences, diagnostics, and applied chemical markets.